BR112014007902A2 - pharmaceutical compositions comprising 40-o- (2-hydroxy) ethyl rapamycin - Google Patents
pharmaceutical compositions comprising 40-o- (2-hydroxy) ethyl rapamycinInfo
- Publication number
- BR112014007902A2 BR112014007902A2 BR112014007902A BR112014007902A BR112014007902A2 BR 112014007902 A2 BR112014007902 A2 BR 112014007902A2 BR 112014007902 A BR112014007902 A BR 112014007902A BR 112014007902 A BR112014007902 A BR 112014007902A BR 112014007902 A2 BR112014007902 A2 BR 112014007902A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxy
- pharmaceutical formulations
- ethyl rapamycin
- pharmaceutical compositions
- dosage forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
resumo patente de invenção: "composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina". a presente invenção refere-se às formulações farmacêuticas de liberação prolongada na forma de multiparticulados compreendendo a 40-o-(2-hidróxi)etil-rapamicina, às formas de dosagem que compreendem ditas formulações farmacêuticas, aos métodos de preparação de ditas formulações farmacêuticas e ditas formas de dosagem, para uso das ditas formulações farmacêuticas e ditas formas de dosagem para a fabricação de um medicamento para o tratamento ou prevenção de doenças ou condições responsivas à inibição da via de sinalização de mtor, tais como, por exemplo, as doenças proliferativas ou imunossupressão.patent summary: "pharmaceutical compositions comprising 40-o- (2-hydroxy) ethyl rapamycin". The present invention relates to multiparticulate sustained release pharmaceutical formulations comprising 40-o- (2-hydroxy) ethyl rapamycin, dosage forms comprising said pharmaceutical formulations, methods for preparing said pharmaceutical formulations and said dosage forms for use in said pharmaceutical formulations and said dosage forms for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of the mtor signaling pathway, such as, for example, proliferative diseases. or immunosuppression.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161544026P | 2011-10-06 | 2011-10-06 | |
PCT/EP2012/069541 WO2013050419A1 (en) | 2011-10-06 | 2012-10-03 | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014007902A2 true BR112014007902A2 (en) | 2017-04-18 |
Family
ID=46968222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014007902A BR112014007902A2 (en) | 2011-10-06 | 2012-10-03 | pharmaceutical compositions comprising 40-o- (2-hydroxy) ethyl rapamycin |
Country Status (23)
Country | Link |
---|---|
US (3) | US20140242162A1 (en) |
EP (1) | EP2763663B1 (en) |
JP (1) | JP6368242B2 (en) |
KR (1) | KR101643219B1 (en) |
CN (1) | CN103874484B (en) |
AR (1) | AR088232A1 (en) |
AU (1) | AU2012320563B2 (en) |
BR (1) | BR112014007902A2 (en) |
CA (1) | CA2850995A1 (en) |
CL (1) | CL2014000844A1 (en) |
CO (1) | CO6930364A2 (en) |
EA (1) | EA025595B1 (en) |
ES (1) | ES2663744T3 (en) |
GT (1) | GT201400062A (en) |
IL (1) | IL231648A0 (en) |
MA (1) | MA35513B1 (en) |
MX (1) | MX2014004166A (en) |
PE (1) | PE20141649A1 (en) |
SG (1) | SG11201400730VA (en) |
TN (1) | TN2014000114A1 (en) |
TW (1) | TWI475993B (en) |
WO (1) | WO2013050419A1 (en) |
ZA (1) | ZA201401961B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201503912A (en) * | 2013-03-19 | 2015-02-01 | Novartis Ag | Pharmaceutical compositions comprising everolimus |
US10709700B2 (en) | 2014-09-15 | 2020-07-14 | Orphazyme A/S | Arimoclomol formulation |
MX2017010872A (en) | 2015-02-27 | 2018-05-07 | Ebbu Llc | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral. |
CN107847491A (en) | 2015-05-20 | 2018-03-27 | 诺华公司 | Everolimus (EVEROLIMUS) and the medicinal combination up to Tuoli former times cloth (DACTOLISIB) |
JP6762158B2 (en) * | 2015-07-28 | 2020-09-30 | 日本化薬株式会社 | Pharmaceutical composition containing rapamycin or a derivative thereof |
EP3329916A4 (en) | 2015-07-28 | 2019-03-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition including rapamycin or derivative thereof, and production method therefor |
JP6793652B2 (en) * | 2015-09-03 | 2020-12-02 | 日本化薬株式会社 | Pharmaceutical composition containing rapamycin or a derivative thereof |
JP6854639B2 (en) * | 2016-01-06 | 2021-04-07 | 日本化薬株式会社 | Pharmaceutical composition containing rapamycin derivative and method for producing the same |
CA3034004C (en) | 2016-08-29 | 2021-08-03 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
TW201825090A (en) | 2016-11-23 | 2018-07-16 | 瑞士商諾華公司 | Methods of enhancing immune response |
WO2018142356A1 (en) * | 2017-02-06 | 2018-08-09 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of everolimus |
KR102051806B1 (en) * | 2018-01-12 | 2019-12-04 | 주식회사 종근당 | Stabilized pharmaceutical formulation comprising Everolimus |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
JP2023520021A (en) * | 2020-03-30 | 2023-05-15 | アイジーアイエー ファーマシューティカルズ インコーポレイテッド | Pediatric Formulations of Tyrosine Kinase Inhibitors |
WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
KR102336007B1 (en) * | 2021-06-23 | 2021-12-07 | 주식회사 진성이앤지 | waterproof-anticorrosion coating material with polyurethane for concrete and waterproof-anticorrosion method using thereof |
WO2023044024A1 (en) * | 2021-09-17 | 2023-03-23 | Novelstar Pharmaceuticals Inc. | Novel ph dependent coating drug delivery system |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
BE1009856A5 (en) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Pharmaceutical composition in the form of a solid release including macrolide and a vehicle. |
EP1421939B9 (en) * | 1998-03-26 | 2011-03-02 | Astellas Pharma Inc. | Sustained release preparation of a macrolide compound like tacrolimus |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
AR045957A1 (en) * | 2003-10-03 | 2005-11-16 | Novartis Ag | PHARMACEUTICAL COMPOSITION AND COMBINATION |
GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
EP1902708A1 (en) * | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Drug comprising stabilized pharmaceutical solid compositions and processes for their preparation |
CA2743491C (en) * | 2008-11-11 | 2016-10-11 | Zelton Dave Sharp | Inhibition of mammalian target of rapamycin |
CN101862297B (en) * | 2009-04-14 | 2012-07-25 | 上海医药工业研究院 | Water-insoluble medicine sustained-release pellet, sustained-release orally disintegrating tablet thereof and preparation method thereof |
-
2012
- 2012-10-03 US US14/349,166 patent/US20140242162A1/en not_active Abandoned
- 2012-10-03 JP JP2014533869A patent/JP6368242B2/en not_active Expired - Fee Related
- 2012-10-03 SG SG11201400730VA patent/SG11201400730VA/en unknown
- 2012-10-03 CA CA2850995A patent/CA2850995A1/en not_active Abandoned
- 2012-10-03 WO PCT/EP2012/069541 patent/WO2013050419A1/en active Application Filing
- 2012-10-03 EP EP12766990.1A patent/EP2763663B1/en active Active
- 2012-10-03 AU AU2012320563A patent/AU2012320563B2/en not_active Ceased
- 2012-10-03 PE PE2014000448A patent/PE20141649A1/en not_active Application Discontinuation
- 2012-10-03 BR BR112014007902A patent/BR112014007902A2/en not_active IP Right Cessation
- 2012-10-03 KR KR1020147008751A patent/KR101643219B1/en active IP Right Grant
- 2012-10-03 CN CN201280049427.XA patent/CN103874484B/en not_active Expired - Fee Related
- 2012-10-03 ES ES12766990.1T patent/ES2663744T3/en active Active
- 2012-10-03 EA EA201490743A patent/EA025595B1/en not_active IP Right Cessation
- 2012-10-03 MX MX2014004166A patent/MX2014004166A/en not_active Application Discontinuation
- 2012-10-04 AR ARP120103699A patent/AR088232A1/en unknown
- 2012-10-05 TW TW101137004A patent/TWI475993B/en not_active IP Right Cessation
-
2014
- 2014-03-18 ZA ZA2014/01961A patent/ZA201401961B/en unknown
- 2014-03-18 TN TNP2014000114A patent/TN2014000114A1/en unknown
- 2014-03-20 IL IL231648A patent/IL231648A0/en unknown
- 2014-04-03 MA MA36880A patent/MA35513B1/en unknown
- 2014-04-04 CO CO14073134A patent/CO6930364A2/en not_active Application Discontinuation
- 2014-04-04 GT GT201400062A patent/GT201400062A/en unknown
- 2014-04-04 CL CL2014000844A patent/CL2014000844A1/en unknown
-
2016
- 2016-11-07 US US15/345,498 patent/US20170049754A1/en not_active Abandoned
-
2018
- 2018-01-24 US US15/879,272 patent/US20180214424A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140242162A1 (en) | 2014-08-28 |
CA2850995A1 (en) | 2013-04-11 |
KR20140058670A (en) | 2014-05-14 |
JP6368242B2 (en) | 2018-08-01 |
US20170049754A1 (en) | 2017-02-23 |
TWI475993B (en) | 2015-03-11 |
TW201318625A (en) | 2013-05-16 |
ES2663744T3 (en) | 2018-04-16 |
CN103874484B (en) | 2016-09-21 |
AU2012320563B2 (en) | 2016-05-12 |
WO2013050419A1 (en) | 2013-04-11 |
IL231648A0 (en) | 2014-05-28 |
EA025595B1 (en) | 2017-01-30 |
KR101643219B1 (en) | 2016-07-27 |
ZA201401961B (en) | 2015-11-25 |
EP2763663A1 (en) | 2014-08-13 |
CN103874484A (en) | 2014-06-18 |
JP2014528431A (en) | 2014-10-27 |
MX2014004166A (en) | 2015-01-15 |
MA35513B1 (en) | 2014-10-02 |
US20180214424A1 (en) | 2018-08-02 |
EA201490743A1 (en) | 2014-07-30 |
EP2763663B1 (en) | 2017-12-27 |
SG11201400730VA (en) | 2014-06-27 |
AU2012320563A1 (en) | 2014-04-24 |
AR088232A1 (en) | 2014-05-21 |
CL2014000844A1 (en) | 2014-09-12 |
CO6930364A2 (en) | 2014-04-28 |
PE20141649A1 (en) | 2014-11-14 |
TN2014000114A1 (en) | 2015-07-01 |
GT201400062A (en) | 2015-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014007902A2 (en) | pharmaceutical compositions comprising 40-o- (2-hydroxy) ethyl rapamycin | |
BR112013022789A2 (en) | pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
PH12014501984A1 (en) | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
BR112015003188A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND USE, AND METHOD FOR TREATMENT OF A RORGAMMAT-MEDIATED DISEASE OR CONDITION IN A PATIENT | |
DOP2013000192A (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK | |
CL2012002497A1 (en) | Compounds derived from imidazopyrimidine, substituted, pde10a inhibitors; preparation procedure; pharmaceutical composition; and its use for the treatment or prevention of psychotic disorders, schizophrenia, parkinson's disease, multiple sclerosis, among others. | |
BR112015010663A8 (en) | sustained release oral dosage forms, and use of ruxolitinib or a pharmaceutically acceptable salt thereof | |
ECSP12011834A (en) | Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses. | |
BR112013018920A2 (en) | nanoparticle compositions, formulations thereof and their uses | |
ECSP13013068A (en) | HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE2 | |
CL2014000806A1 (en) | Compounds derived from 1-arylcarbonyl-4-oxy-piperidino; pharmaceutical composition that includes them; Use for the prevention or treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis. | |
ECSP12012318A (en) | PIRAZOLIL QUINAZOLINA CINASA INHIBITORS | |
AR090491A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND DIMETILO FUMARATE | |
CR11455A (en) | NEW CYCL HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | |
CR20140144A (en) | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
BR112014005025A2 (en) | pharmaceutical composition for use in the treatment of a neurodegenerative disease | |
CR20120549A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE | |
PE20150353A1 (en) | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAENO 3-SUBSTITUTED, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
BR112014012459A2 (en) | 2h-indazoles as ep2 receptor antagonists | |
MX344846B (en) | Combination of active loaded granules with additional actives. | |
DOP2013000314A (en) | TYPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB | |
BR112015030431A2 (en) | modified release formulation | |
UY33723A (en) | ? COMPOUNDS AND ITS USE FOR TREATMENT OF DISEASES RELATED TO Aß ?. | |
BR112014009760A2 (en) | sialic acid analogs, their use and pharmaceutical composition and sustained release pharmaceutical composition comprising them | |
ES2403549R1 (en) | Agomelatine co-crystals with co-crystal formers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2482 DE 31-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |